Key Drivers
- Strong Balance Sheet
- Rich Valuation
- Weak Cash Conversion
AIAI Summary
BIO should be viewed less as a growth re-rating and more as a cash-rich, high-quality franchise whose upside is capped by flat top-line growth and ongoing Life Science/China weakness, so the key question is whether Clinical Diagnostics and margin discipline can keep earnings stable enough to justify the premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Balance Sheet
- •Rich Valuation
- •Weak Cash Conversion
BIO has a strong, low-debt balance sheet and solid profitability, but its valuation is now rich and cash conversion has softened.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Momentum intact
- •Mild pullback
BIO remains in a constructive last month uptrend with higher highs and higher lows, but after a sharp run to $362, near-term upside may pause unless it holds the mid-$350s.
Sharp run-up from $300.98 to $356.26, peaking at $362.08 before mild profit-taking
Sentiment & News
Key News Insights:
- •Earnings beat
- •Mixed valuation
- •Global contract wins
Bio-Rad's earnings beat was offset by mixed valuation and flat revenue trends, while BIO-key's international contract wins and improving results point to selective strength in the group.
The news is mildly supportive overall, but Bio-Rad likely stays range-bound until revenue growth broadens and regional trends improve
Similar Companies in Healthcare
Other companies in the same sector with AI ratings